Chemokine

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Jeudi, avril 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus

Retrieved on: 
Jeudi, mars 28, 2024
Fibroblast, Conditional sentence, Risk, Communication, Form, Patient, Trial of the century, Chemokine, Cytokine, Patent, Therapy, Vaccine

HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast cell-based technology for the potential treatment of Lupus.

Key Points: 
  • HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast cell-based technology for the potential treatment of Lupus.
  • “Our scientists continue to explore clinical opportunities to treat chronic diseases using fibroblast cells, which are natural immune modulators.
  • Successfully leveraging fibroblasts to achieve a durable immune modulation may serve as a potential treatment for Lupus, a debilitating autoimmune disease,” noted Founder & CEO of FibroBiologics, Pete O’Heeron.
  • Fibroblast cells may offer a broad range of potential clinical benefits for patients suffering from chronic disease,” added Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D.
    For more information, please visit FibroBiologics’ website or email FibroBiologics at: [email protected] .

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
Mardi, avril 9, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, B cell, Immunity, Cell, Patient, City, Tumor microenvironment, Cancer, AACR, Chemokine, Clinical trial, Immune system, Virus, Potyvirus, Poster, Vaccine

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Lundi, mars 25, 2024
Toxicity, B cell, CD8, Research, Cancer research, AACR, Chemokine, Therapy, Cytokine, Immune system, Poster, Viral, Decoy, Bacteria, Vaccine

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, will present a poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday morning, April 10th. An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research. The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.

Key Points: 
  • An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research.
  • The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.
  • The activity was associated with induction of human tumor cell killing by Decoy bacteria in the presence of immune cells.
  • Potentially unacceptable toxicity from this breadth of immune activation is avoided by using systemically administered killed bacteria as a delivery vehicle.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, mars 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Lundi, mars 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mercredi, mars 13, 2024
Research, Conference, Immunotherapy, Patient, Sale, Viral, Society, Chemokine, Therapy, Cytokine, European Patent Convention, Safety, Cryptocurrency

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.
  • General and administrative expenses for the three-month periods ended December 31, 2023 and 2022, were $2.2 million.
  • Loss per share for the twelve-month period ended December 31, 2023 was $1.83, compared with $1.73 for the twelve-month period ended December 31, 2022.
  • There was no net cash provided by or used in financing activities for the twelve-month periods ended December 31, 2023 and 2022.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Mercredi, mars 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Jeudi, avril 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

Key Points: 
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: "We are excited to join forces with Alamar to advance proteomics research.
  • This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Jeudi, avril 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.